Dyne Therapeutics, Inc.
19.19USD
-1.1200 (-5.51%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.89▼ | $-0.76 | 1 | 9 |
| Next quarter | $-0.89▼ | $-0.78 | 2 | 8 |
| Current year | $-3.55▼ | $-3.08 | 0 | 11 |
| Next year | $-3.36▼ | $-2.98 | 2 | 8 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.75 | $-1.08 | -0.33 (-44.3%) |
| 2026-03-31 | $-0.78 | $-0.73 | +0.05 (+6.6%) |
| 2025-12-31 | $-0.76 | $-0.73 | +0.03 (+4.4%) |
| 2025-09-30 | $-0.85 | $-0.76 | +0.09 (+10.1%) |
97 ratings from 19 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Morgan Stanley | Maintained | Overweight | $45 $36 | Sep 9, 2026 |
| JP Morgan | Downgraded from Neutral | Underweight | $17 $10 | Sep 9, 2026 |
| RBC Capital | Maintained | Outperform | $35 $30 | Sep 9, 2026 |
| Baird | Maintained | Outperform | $30 $26 | Sep 9, 2026 |
| Morgan Stanley | Maintained | Overweight | $47 $45 | Jul 31, 2026 |
| RBC Capital | Maintained | Outperform | $30 $35 | Jul 30, 2026 |
| Cantor Fitzgerald | Initiated | Overweight | — | Jul 23, 2026 |
| TD Cowen | Initiated | Buy | — | Jun 26, 2026 |
| Evercore ISI Group | Maintained | Outperform | $34 $33 | May 15, 2026 |
| Bernstein | Maintained | Market Perform | $23 $24 | May 13, 2026 |
| Chardan Capital | Maintained | Buy | $38 | Mar 9, 2026 |
| Morgan Stanley | Maintained | Overweight | $50 $47 | Mar 3, 2026 |
| Chardan Capital | Maintained | Buy | $38 | Mar 3, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $60 $50 | Mar 3, 2026 |
| JP Morgan | Maintained | Neutral | $17 $16 | Jan 20, 2026 |
| Evercore ISI Group | Maintained | Outperform | $38 $36 | Dec 15, 2025 |
| Stifel | Maintained | Buy | $36 $39 | Dec 11, 2025 |
| Oppenheimer | Upgraded from Perform | Outperform | $11 $40 | Dec 10, 2025 |
| Morgan Stanley | Maintained | Overweight | $46 $50 | Dec 9, 2025 |
| Chardan Capital | Maintained | Buy | $38 | Dec 9, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $46 $60 | Dec 8, 2025 |
| JP Morgan | Maintained | Neutral | $18 $17 | Nov 14, 2025 |
| Oppenheimer | Maintained | Perform | $13 $11 | Nov 12, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $38 $46 | Nov 6, 2025 |
| RBC Capital | Maintained | Outperform | $23 $30 | Nov 6, 2025 |
102 filings from 15 insiders · 8 buy / 30 sell over 6m
Officers and directors of DYN, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Friedl-Naderer JohannaOfficer, Chief Commercial Officer | Sell | 185 | $18.88 | $3k | Sep 8, 2026 |
| Kerr DouglasOfficer, Chief Medical Officer | Sell | 1.3k | $18.88 | $24k | Sep 8, 2026 |
| Cox JohnDirector; Officer, CEO & President | Sell | 5.7k | $18.88 | $107k | Sep 8, 2026 |
| Friedl-Naderer JohannaOfficer, Chief Commercial Officer | Sell | 900 | $24.35 | $22k | Sep 4, 2026 |
| Kerr DouglasOfficer, Chief Medical Officer | Sell | 3.7k | $24.35 | $91k | Sep 4, 2026 |
| RHODES JASON PDirector | Sellindirect | 2.59M | $25.00 | $65.18M | Aug 14, 2026 |
| LUCERA ERICK J.Chief Financial Officer | Sell | 1.8k | $26.28 | $47k | Aug 13, 2026 |
| KERR DOUGLASOfficer | Sell | 1.6k | $26.28 | $41k | Aug 13, 2026 |
| COX JOHNChief Executive Officer | Sell | 5.0k | $26.28 | $131k | Aug 13, 2026 |
| FRIEDL-NADERER JOHANNAOfficer | Sell | 226 | $26.28 | $6k | Aug 13, 2026 |
| KERSTEN DIRKDirector | Sellindirect | 261.5k | $25.50 | $6.67M | Jul 27, 2026 |
| RHODES JASON PDirector | Sellindirect | 777.5k | $22.79 | $17.86M | Jul 7, 2026 |
| RHODES JASON PDirector | Sellindirect | 504.7k | $21.14 | $10.71M | Jun 29, 2026 |
| LUCERA ERICK J.Chief Financial Officer | Sell | 2.4k | $20.37 | $48k | Jun 25, 2026 |
| RHODES JASON PDirector | Sellindirect | 267.8k | $21.02 | $5.65M | Jun 25, 2026 |
| KERSTEN DIRKDirector | Sellindirect | 264.0k | $20.57 | $5.46M | Jun 23, 2026 |
| KERSTEN DIRKDirector | Sellindirect | 84.4k | $20.07 | $1.70M | Jun 18, 2026 |
| KERR DOUGLASOfficer | Sell | 887 | $18.33 | $16k | Jun 16, 2026 |
| COX JOHNChief Executive Officer | Sell | 2.7k | $18.33 | $49k | Jun 16, 2026 |
| FRIEDL-NADERER JOHANNAOfficer | Sell | 145 | $18.33 | $3k | Jun 16, 2026 |
No analyst notes on DYN yet.
Analyst Ratings
14 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 3 | 13 | 0 | 0 | 1 | Buy2.00 |
| 1 mo ago | 3 | 13 | 1 | 0 | 0 | Buy1.88 |
| 2 mo ago | 3 | 13 | 1 | 0 | 0 | Buy1.88 |
| 3 mo ago | 3 | 12 | 2 | 0 | 0 | Buy1.94 |